BAQSIMI: payments to doctors
Payments that named BAQSIMI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 9,076
- Transactions
- 35,025
- Average per transaction
- $35
The per-transaction average — $35 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,076 providers the average total is $136, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $1,219,819 | 98.6% |
| Amphastar Pharmaceuticals, Inc. | $13,978 | 1.1% |
| Eli Lilly | $3,900 | 0.3% |
| Eli Lilly Export S.A. Puerto Rico Branch | $20 | 0.0% |